President Cyril Ramaphosa launched the rollout of Lenacapavir, a long-acting injectable HIV prevention drug, in Secunda, Mpumalanga, on Friday [1].
The introduction of this medication represents a shift in HIV prevention strategy by reducing the frequency of doses required to protect individuals from infection. By providing a long-acting alternative to daily pills, the government aims to increase adherence and accessibility for high-risk populations.
The launch occurred on June 5, 2026 [2], as part of a broader effort to strengthen the national response to the HIV/AIDS epidemic. The event in Secunda serves as the starting point for the distribution of the drug across the region.
Lenacapavir is designed as a preventive measure to block the virus from establishing an infection in the body. This new tool is intended to complement existing prevention methods, offering a more sustainable option for those who struggle with the logistics of daily medication.
Government officials said the rollout is a critical step in reducing new infection rates across South Africa. The long-acting nature of the injection is expected to remove barriers related to pharmacy visits, and the social stigma often associated with daily pill regimens.
Public health coordinators in Mpumalanga are now overseeing the initial phase of the distribution. The program will target specific demographics to ensure the most vulnerable populations receive the preventative treatment first.
“President Cyril Ramaphosa launched the rollout of Lenacapavir, a long-acting injectable HIV prevention drug.”
The rollout of Lenacapavir marks a transition toward long-acting prophylaxis in South Africa, which could significantly lower the failure rate of HIV prevention caused by missed daily doses. By shifting the burden of adherence from the patient to a periodic clinical visit, the state may see a decrease in new infections among populations with limited healthcare access.
